Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:TVTX News 24 December 2025 - 13 January 2026

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals shares fell 10.6% after the FDA extended its review of partner Travere’s Filspari label expansion, resetting the decision deadline to April 13. Travere shares dropped 19%. The FDA classified the latest filing as a “major amendment” but did not request new safety or manufacturing data. The broader biotech sector was little changed.
13 January 2026
···
Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics shares fell 19% Tuesday after the FDA extended its review of Filspari for broader use in kidney disease, pushing the decision deadline to April 13. The stock hit an intraday low of $22.35 before recovering. Travere forecast $127 million in Q4 U.S. net product sales and ended 2025 with $323 million in cash and equivalents. Analyst Joseph Schwartz warned a formal rejection from the FDA remains possible.
13 January 2026
··
Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics shares dropped 5.3% to $36.09 Tuesday ahead of the FDA’s Jan. 13 decision on expanding kidney drug Filspari’s label. Options trading surged, with heavy put activity at the $35 strike. Chief Medical Officer Jula Inrig disclosed a planned sale of 15,000 shares to cover taxes. CEO Eric Dube will present at the J.P. Morgan Healthcare Conference on Jan. 12.
6 January 2026
··
Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Travere Therapeutics shares fell 3.8% to $37.39 Tuesday afternoon, outpacing declines in biotech ETFs. SEC filings showed Chief Medical Officer Jula Inrig and Chief Commercial Officer Pieter Heerma sold shares on Dec. 24 under pre-arranged 10b5-1 plans. The moves come weeks before a key FDA decision on Filspari for FSGS, set for Jan. 13, 2026. Trading volume reached about 893,000 shares.
30 December 2025
Travere Therapeutics (TVTX) Stock Watch: Pre‑Market Focus on the Jan. 13 FDA Decision After a 14% Rally

Travere Therapeutics (TVTX) Stock Watch: Pre‑Market Focus on the Jan. 13 FDA Decision After a 14% Rally

Travere Therapeutics shares closed at $40.28 on Dec. 24, up 13.9% after bullish analyst commentary and anticipation of an FDA decision on FILSPARI for FSGS by Jan. 13, 2026. Early pre-market trading Friday showed TVTX around $40.6. The FDA dropped plans for an advisory committee meeting, which some investors see as a positive sign. Trading volume remains light due to the holiday.
26 December 2025
Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics shares jumped about 15% to over $40 in early trading on Dec. 24, 2025, hitting new highs during a holiday-shortened session. The surge followed investor anticipation of an FDA decision on FILSPARI for FSGS, expected by Jan. 13, 2026. No company news was released that day. The FDA previously waived an advisory committee review for the application.
24 December 2025
·

Stock Market Today

Keppel stock price in focus as broker lifts target and dividend clock ticks

Keppel stock price in focus as broker lifts target and dividend clock ticks

8 February 2026
Keppel shares closed at S$11.64 on Friday, up 0.17%, outperforming the Straits Times Index. UOB Kay Hian raised its target price to S$13.23 after Keppel announced a 38% higher FY2025 dividend, with key dates set for April. The M1 sale remains delayed pending regulatory approval. Investors await updates on asset sales and dividend plans when trading resumes Monday.
DBS share price: DBS Group Holdings stock in focus before Feb 9 earnings

DBS share price: DBS Group Holdings stock in focus before Feb 9 earnings

8 February 2026
DBS closed at S$59.30 on Friday, down 0.6%, ahead of its full-year results due before market open on Feb. 9. Singapore shares fell 0.8% the same day as regional markets slid. Investors await updates on DBS’s margins and capital return plan. Singapore’s Budget 2026 is set for Feb. 12, with UOB and OCBC results later this month.
Go toTop